Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'We are ready': NASA still on track to launch Artemis 2 astronauts to the moon April 1 - 2KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- 310 Asian Countries Perfect for Solo Female Travelers
- 4Beddings of 2024: Track down Your Ideal Fit for a Tranquil Rest
- 5Very good quality Greens All over The Planet
- Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- Tremendous Spelunking: Cool Caverns All over the Planet
- Flights canceled at 40 U.S. airports: Follow live updates as FAA cuts to air traffic take effect amid government shutdown
- 4 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- US healthcare spending soars to over $5 trillion in 2024
- UN warns civil liberties under threat due to war in Middle East
- Savvy Watches: Which One Is Appropriate for You?
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
